European monoclonal antibodies market is estimated to grow at a CAGR of 7.2% during the forecast period. The increasing prevalence of cancer and rising approvals for monoclonal antibodies are some pivotal factors encouraging market growth. As per the World Health Organization (WHO), in Europe, there were nearly 4.2 million new cancer incidences reported in 2018. The most common forms of cancer reported in the region include breast cancer (12.4%), colorectum (11.8%), lung (11.1%), prostate (10.6%), bladder (4.7%), and other cancers (49.4%). Monoclonal antibodies act as one of the potentially used immune system proteins produced in the lab, which is highly useful in cancer treatment. These antibodies are developed naturally by the body and support the immune system to detect germs that cause disease, including viruses and bacteria, and point them for destruction. Monoclonal antibodies detect specific targets and thereby work to destroy cancer cells.
Get Free Sample link @ https://www.omrglobal.com/request-sample/european-monoclonal-antibodies-market
European monoclonal antibodies market is segmented based on source and application. Based on the source, the market is classified into murine, chimeric, human, and humanized. Humanized monoclonal antibodies are expected to have potential application as it has major benefits compared to original mouse monoclonal antibodies. The monoclonal antibodies immunogenicity is reduced and the serum half-life of the monoclonal antibodies in humans is significantly enhanced. It is an established technique to reduce the immunogenicity of monoclonal antibodies from xenogeneic sources (usually rodent). In addition, it is used to improve the activation of the human immune system. Based on the application, the market is classified into cancer, infectious diseases, auto-immune diseases, inflammatory diseases, and others.
A full report of European Monoclonal Antibodies Market available @ https://www.omrglobal.com/industry-reports/european-monoclonal-antibodies-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
European Monoclonal Antibodies Market by Source
- Murine
- Chimeric
- Human
- Humanized
European Monoclonal Antibodies Market by Application
- Cancer
- Infectious Diseases
- Auto-Immune Diseases
- Inflammatory Diseases
- Others
Regional Analysis
- UK
- Germany
- France
- Spain
- Italy
- Rest of European
Company Profiles
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Hoffmann-La Roche AG
- Genmab A/S
- GlaxoSmithKline plc
- Innate Pharma S.A.
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
The Report Covers
- Comprehensive research methodology of the European monoclonal antibodies market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the European monoclonal antibodies market.
- Insights about market determinants which are stimulating the European monoclonal antibodies market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-monoclonal-antibodies-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
